## CVS PE Stream Chart Analysis **Current Valuation (Latest Data Point):** As of the most recent data point (mid-March 2026), CVS is trading at a monthly average price of approximately **$73.02**. Comparing this to the PE boundary lines at the same date, the lowest PE stream ( **9.1 times**, price boundary at ~$12.75) sits well below the current price, while the second PE stream (**49.6 times**, boundary at ~$69.28) is just beneath the current price level, and the third PE stream (**90.1 times**, boundary at ~$125.83) is well above. This positions CVS squarely in the **"Value"** zone — trading between the 9.1 times and 49.6 times PE boundaries. The stock is trading modestly above the 49.6 times boundary (~$69.28), suggesting it has recently crossed into the lower end of the **"Fair"** interval, reflecting a relatively modest valuation compared to its historical PE range. All higher PE boundaries (90.1 times at ~$125.83, 130.6 times at ~$182.37, 171.1 times at ~$238.91, and 211.6 times at ~$295.44) remain far above the current price, confirming there is no sign of overvaluation at present. **Historical Valuation Trend:** Looking back from early 2021 through mid-2026, CVS's valuation trajectory has been notably volatile, reflecting significant earnings instability. From Q1'21 through Q1'22, the stock price ranged between ~$61 and ~$91, consistently trading well below all PE stream boundaries — firmly in the **"Undervalued"** to **"Value"** zone — as the PE boundaries during this period were extremely elevated (e.g., the 9.1 times boundary was around $50–$56), indicating the market was pricing CVS at a very low earnings multiple. A sharp inflection occurred around Q3'22, when the PE stream boundaries collapsed dramatically — the 9.1 times boundary dropped from ~$56 to ~$21 — suggesting a significant earnings deterioration. This caused the stock price (~$87) to surge relative to the PE bands, briefly pushing CVS into a much higher valuation zone. From Q4'22 through mid-2023, the boundaries partially recovered but remained suppressed, and the stock price declined from ~$87 to the low $60s, drifting back toward the **"Value"** and **"Fair"** intervals. Another notable boundary reset occurred around Q3'23, when the PE streams jumped sharply upward (e.g., the 9.1 times boundary spiked to ~$60), briefly placing CVS back in the **"Undervalued"** zone relative to the new earnings baseline. However, from late 2024 onward, the PE boundaries collapsed again — particularly dramatically in Q3'25, where the 9.1 times boundary fell to just ~$3.39 — indicating another severe earnings contraction. The stock price, ranging between ~$47 and ~$79 during this period, consequently moved well above the lowest PE bands, reflecting elevated relative valuation. The river chart's pattern of sharp rises and falls in the PE boundaries underscores that CVS's earnings have been highly unstable over this period, making the PE stream chart a challenging but revealing tool — the repeated boundary collapses and recoveries suggest the company is navigating significant structural headwinds, and investors should exercise caution when interpreting any single valuation zone in isolation.